Oral Misoprostol for Induction of Labour: An Initial Australian Experience
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2026
DOI: 10.1111/ajo.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2026. Verfasst von Nimani Vasana Hettiarachchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Mater Mothers Hospital, South Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Misoprostol, Labor, Induced, Oxytocics. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Background
Misoprostol, a prostaglandin E1 analogue, is widely used internationally for the induction of labour (IOL) but was recently approved in Australia in a 25‐μg oral tablet form (Angusta). While previous studies suggest oral misoprostol may reduce Caesarean section rates secondary to uterine hyperstimulation compared to vaginal Dinoprostone, its efficacy and feasibility in an Australian clinical setting remain unclear. This study evaluates the implementation of oral misoprostol for the IOL in multiparous women at a tertiary maternity hospital.
Aims
To assess the clinical outcomes, patient satisfaction, and resource implications of introducing oral misoprostol for labour induction, comparing it to the established vaginal Prostaglandin E2 (PGE2) protocol. Materials and Methods A clinical protocol for oral misoprostol induction was developed following a literature review and expert consultation. A retrospective service evaluation was conducted after the first 100 patients, comparing key labour and birth outcomes between oral misoprostol and historical vaginal PGE2 cohorts. Data were extracted from hospital records, and propensity score matching was applied to balance baseline characteristics. Patient satisfaction was assessed via a survey.
Results
No significant differences were found in induction‐to‐delivery time, mode of birth, oxytocin use or adverse neonatal outcomes. Epidural use was higher in the oral misoprostol group. Medication costs and staffing requirements were also increased. Patient satisfaction was comparable between groups.
Conclusions
In a setting with an early artificial rupture of membranes (ARM) protocol, oral misoprostol did not provide clear advantages over vaginal PGE2. Further research is needed to optimise induction protocols in the Australian context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Mater Mothers Hospital, South Brisbane, Queensland, Australia.
- Mater Hospital, South Brisbane, Queensland, Australia.
- Birthing and Ambulatory Services, Mater Mothers Hospital, South Brisbane, Queensland, Australia.
ORCID-Profile: Nimani Vasana Hettiarachchi
Zitieren
APA
Hettiarachchi, N. V., Janssens, S., Beckmann, M., & Sharif, R. (2026). Oral Misoprostol for Induction of Labour: An Initial Australian Experience. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.70087
Vancouver
Hettiarachchi NV, Janssens S, Beckmann M, Sharif R. Oral Misoprostol for Induction of Labour: An Initial Australian Experience. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2026. doi:10.1111/ajo.70087
BibTeX
@article{Hettiarachchi2026,
author = {Hettiarachchi, Nimani Vasana and Janssens, Sarah and Beckmann, Michael and Sharif, Razia},
title = {Oral Misoprostol for Induction of Labour: An Initial Australian Experience},
journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
year = {2026},
doi = {10.1111/ajo.70087}
}
EUVIMED